[Jeffrey Roberts]

GSK Lotronex Risk Could Be Explored Through Patient Use Survey, IBS Group SuggestsGlaxoSmithKline�s Lotronex risk potential could be characterized by a survey of irritable bowel syndrome patients who are willing to take the drug, the Lotronex Action Group said in comments prepared for FDA�s Risk Management Subcommittee's April 23 meeting.Complete story is here: http://www.ibsgroup.org/other/FDAReports2002Apr19.html Posted: Friday, April 19, 2002Copywrite FDC Reports, Inc.